MA49726B1 - Formulation d'anticorps anti-cgrp - Google Patents

Formulation d'anticorps anti-cgrp

Info

Publication number
MA49726B1
MA49726B1 MA49726A MA49726A MA49726B1 MA 49726 B1 MA49726 B1 MA 49726B1 MA 49726 A MA49726 A MA 49726A MA 49726 A MA49726 A MA 49726A MA 49726 B1 MA49726 B1 MA 49726B1
Authority
MA
Morocco
Prior art keywords
antibody formulation
cgrp antibody
headaches
episodic
chronic
Prior art date
Application number
MA49726A
Other languages
English (en)
Other versions
MA49726A (fr
Inventor
Anant N. SHARMA
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of MA49726A publication Critical patent/MA49726A/fr
Publication of MA49726B1 publication Critical patent/MA49726B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne des formulations pharmaceutiques d'anticorps anti-CGRP, et leurs procédés d'utilisation, lesdites formulations étant utiles dans le traitement des migraines, des maux de tête épisodiques, des maux de tête chroniques, des céphalées en grappe chroniques, et des céphalées en grappe épisodiques.
MA49726A 2015-06-17 2016-06-08 Formulation d'anticorps anti-cgrp MA49726B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562180905P 2015-06-17 2015-06-17
EP16729483.4A EP3310809B1 (fr) 2015-06-17 2016-06-08 Formulation d'anticorps anti-cgrp
PCT/US2016/036407 WO2016205037A1 (fr) 2015-06-17 2016-06-08 Formulation d'anticorps anti-cgrp

Publications (2)

Publication Number Publication Date
MA49726A MA49726A (fr) 2020-06-10
MA49726B1 true MA49726B1 (fr) 2025-02-28

Family

ID=56131672

Family Applications (1)

Application Number Title Priority Date Filing Date
MA49726A MA49726B1 (fr) 2015-06-17 2016-06-08 Formulation d'anticorps anti-cgrp

Country Status (31)

Country Link
US (3) US11498959B2 (fr)
EP (2) EP4470557A3 (fr)
JP (1) JP6438599B2 (fr)
KR (1) KR102000867B1 (fr)
CN (3) CN118356393A (fr)
AR (2) AR104847A1 (fr)
AU (1) AU2016280555B2 (fr)
BR (1) BR112017023374A2 (fr)
CA (1) CA2984185A1 (fr)
DK (1) DK3310809T3 (fr)
EA (1) EA037580B1 (fr)
ES (1) ES3000607T3 (fr)
FI (1) FI3310809T3 (fr)
HR (1) HRP20241660T1 (fr)
HU (1) HUE069368T2 (fr)
IL (2) IL292562A (fr)
JO (1) JO3772B1 (fr)
LT (1) LT3310809T (fr)
MA (1) MA49726B1 (fr)
MD (1) MD3310809T2 (fr)
MX (1) MX395147B (fr)
MY (1) MY184266A (fr)
NZ (1) NZ737046A (fr)
PL (1) PL3310809T3 (fr)
PT (1) PT3310809T (fr)
RS (1) RS66243B1 (fr)
SI (1) SI3310809T1 (fr)
TW (1) TWI725973B (fr)
UA (1) UA120881C2 (fr)
WO (1) WO2016205037A1 (fr)
ZA (1) ZA201707324B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12257272B2 (en) 2015-12-24 2025-03-25 Seed Health, Inc. Method and system for reducing the likelihood of developing depression in an individual
US11951140B2 (en) 2011-02-04 2024-04-09 Seed Health, Inc. Modulation of an individual's gut microbiome to address osteoporosis and bone disease
US12279989B2 (en) 2011-02-04 2025-04-22 Seed Health, Inc. Method and system for increasing beneficial bacteria and decreasing pathogenic bacteria in the oral cavity
US11844720B2 (en) 2011-02-04 2023-12-19 Seed Health, Inc. Method and system to reduce the likelihood of dental caries and halitosis
US11951139B2 (en) 2015-11-30 2024-04-09 Seed Health, Inc. Method and system for reducing the likelihood of osteoporosis
US12533312B2 (en) 2011-02-04 2026-01-27 Seed Health, Inc. Method and system for preventing sore throat in humans
US11998479B2 (en) 2011-02-04 2024-06-04 Seed Health, Inc. Method and system for addressing adverse effects on the oral microbiome and restoring gingival health caused by sodium lauryl sulphate exposure
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US11826388B2 (en) 2013-12-20 2023-11-28 Seed Health, Inc. Topical application of Lactobacillus crispatus to ameliorate barrier damage and inflammation
US11969445B2 (en) 2013-12-20 2024-04-30 Seed Health, Inc. Probiotic composition and method for controlling excess weight, obesity, NAFLD and NASH
US12329783B2 (en) 2013-12-20 2025-06-17 Seed Health, Inc. Method and system to improve the health of a person's skin microbiome
US11998574B2 (en) 2013-12-20 2024-06-04 Seed Health, Inc. Method and system for modulating an individual's skin microbiome
US12005085B2 (en) 2013-12-20 2024-06-11 Seed Health, Inc. Probiotic method and composition for maintaining a healthy vaginal microbiome
US11980643B2 (en) 2013-12-20 2024-05-14 Seed Health, Inc. Method and system to modify an individual's gut-brain axis to provide neurocognitive protection
US11833177B2 (en) 2013-12-20 2023-12-05 Seed Health, Inc. Probiotic to enhance an individual's skin microbiome
US12246043B2 (en) 2013-12-20 2025-03-11 Seed Health, Inc. Topical application to treat acne vulgaris
US11839632B2 (en) 2013-12-20 2023-12-12 Seed Health, Inc. Topical application of CRISPR-modified bacteria to treat acne vulgaris
HRP20240159T1 (hr) 2014-03-21 2024-04-12 Teva Pharmaceuticals International Gmbh Antagonistička protutijela usmjerena protiv peptida povezanog s genom kalcitonina i postupci koji ih koriste
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
MX2019003338A (es) * 2016-09-23 2019-09-26 Teva Pharmaceuticals Int Gmbh Tratamiento de cefalea en racimos.
KR20220031944A (ko) 2016-09-23 2022-03-14 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
WO2018160897A1 (fr) 2017-03-02 2018-09-07 Beth Israel Deaconess Medical Center, Inc. Prévention de céphatée post-ictale
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
MX2020010320A (es) * 2018-04-02 2021-01-08 Amgen Inc Composiciones de erenumab y usos de las mismas.
WO2019231800A1 (fr) * 2018-05-31 2019-12-05 Eli Lilly And Company Anticorps anti-cgrp pour le traitement des migraines liées aux menstruations
EA202190815A1 (ru) * 2018-09-20 2021-07-02 Тева Фармасьютикалз Интернэшнл Гмбх Инъекторная пружина для состаренного, предварительно заполненного шприца и автоинъектор
US11639380B2 (en) 2019-01-08 2023-05-02 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-CGRP antibodies
BR112020027063A2 (pt) * 2019-05-02 2021-11-16 H Lundbeck As Tratamento de dor de cabeça com uso de anticorpos anti-cgrp
CA3077973A1 (fr) 2020-04-06 2021-10-06 H. Lundbeck A/S Traitement du symptome le plus perturbant associe a la migraine au moyen d`anticorps anti-cgrp
JP2024509165A (ja) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー 片頭痛の治療及び／又は発生の低減
WO2023026205A1 (fr) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Traitement préventif de la migraine

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ290342B6 (cs) 1992-10-02 2002-07-17 Genetics Institute Inc. Kompozice stabilní při skladování, obsahující koagulační faktor VIII a neiontovou povrchově aktivní látku a způsob její výroby
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
IL161677A0 (en) * 2001-11-08 2004-09-27 Protein Design Labs Stable liquid pharmaceutical formulation of igg antibodies
NO346070B1 (no) 2003-02-10 2022-01-31 Biogen Ma Inc Stabil, vandig, farmasøytisk formulering og fremgangsmåte for fremstilling derav.
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
KR20070107079A (ko) 2005-01-28 2007-11-06 와이어쓰 안정화된 액체 폴리펩타이드 제형
WO2006096461A2 (fr) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Compositions d'anticorps contre m-csf
US9168286B2 (en) * 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
NZ597082A (en) * 2005-10-13 2013-11-29 Human Genome Sciences Inc Methods and Compositions for Use in Treatment of Patients with Autoantibody Positive Diseases
JP5123197B2 (ja) 2005-11-14 2013-01-16 ライナット ニューロサイエンス コーポレイション カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体およびその使用方法
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
BRPI0721097A2 (pt) 2006-12-11 2014-07-01 Hoffmann La Roche Formulação parenteral de anticorpo abeta
EP2114451A2 (fr) * 2007-01-09 2009-11-11 Wyeth a Corporation of the State of Delaware Préparations d'anticorps ant-il-13 et leurs utilisations
WO2008116103A2 (fr) * 2007-03-22 2008-09-25 Imclone Llc Formulations d'anticorps stables
AU2008232903B9 (en) 2007-03-30 2013-09-05 Medimmune Llc Antibodies with decreased deamidation profiles
EP2146746A4 (fr) * 2007-04-18 2011-03-23 Janssen Alzheimer Immunotherap Prévention et traitement d'angiopathie amyloïde cérébrale
TR201802935T4 (tr) * 2008-09-19 2018-03-21 Pfizer Stabil sıvı antikor formülasyonu.
EP2362767B1 (fr) 2008-10-29 2017-12-06 Ablynx N.V. Formulations de molécules de liaison d'antigène monodomaines
BRPI0921845A2 (pt) * 2008-11-12 2019-09-17 Medimmune Llc formulação aquosa estéril estável, forma de dosagem unitária farmacêutica, seringa pré-carregada, e, métodos para tratar uma doença ou distúrbio, para tratar ou prevenir rejeição, para esgotar células t que expressam icos em um paciente humano, e para interromper arquitetura central germinal em um órgão linfóide secundário de um primata
AU2009319856A1 (en) * 2008-11-28 2010-06-03 Abbvie Inc. Stable antibody compositions and methods for stabilizing same
EP2196476A1 (fr) 2008-12-10 2010-06-16 Novartis Ag Formulation d'anticorps
CN102413839A (zh) * 2009-03-06 2012-04-11 医学免疫有限责任公司 人源化抗cd19抗体制剂
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
AR081434A1 (es) * 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
PL3831406T3 (pl) * 2010-08-23 2024-09-09 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
CA2830806C (fr) * 2011-03-31 2020-05-12 Merck Sharp & Dohme Corp. Formulations stables d'anticorps diriges contre le recepteur humain pd-1 de la mort programmee et traitements associes
EP3662932B1 (fr) * 2011-05-20 2021-04-07 H. Lundbeck A/S Compositions anti-cgrp et leur utilisation
HK1200464A1 (en) 2011-10-24 2015-08-07 Abbvie Inc. Immunobinders directed against tnf
US20140227250A1 (en) * 2012-08-23 2014-08-14 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
CN105051064A (zh) * 2013-01-24 2015-11-11 葛兰素史克知识产权开发有限公司 抗TNF-α抗原结合蛋白
HRP20240159T1 (hr) * 2014-03-21 2024-04-12 Teva Pharmaceuticals International Gmbh Antagonistička protutijela usmjerena protiv peptida povezanog s genom kalcitonina i postupci koji ih koriste
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
JP6592600B2 (ja) * 2015-10-30 2019-10-16 イーライ リリー アンド カンパニー 抗ｃｇｒｐ／抗ｉｌ−２３二重特異性抗体及びその使用

Also Published As

Publication number Publication date
US20230159628A1 (en) 2023-05-25
EP3310809B1 (fr) 2024-10-16
AR133453A2 (es) 2025-10-01
BR112017023374A2 (pt) 2018-07-24
KR20180002858A (ko) 2018-01-08
US20220112277A1 (en) 2022-04-14
FI3310809T3 (fi) 2024-12-07
CN114948847A (zh) 2022-08-30
JP6438599B2 (ja) 2018-12-19
MD3310809T2 (ro) 2025-03-31
PL3310809T3 (pl) 2025-01-27
AU2016280555A1 (en) 2017-11-16
WO2016205037A1 (fr) 2016-12-22
LT3310809T (lt) 2025-01-10
KR102000867B1 (ko) 2019-07-16
UA120881C2 (uk) 2020-02-25
SI3310809T1 (sl) 2025-03-31
EP4470557A2 (fr) 2024-12-04
IL255443B (en) 2022-06-01
CN107787229A (zh) 2018-03-09
IL292562A (en) 2022-06-01
EA201792359A1 (ru) 2018-05-31
AU2016280555B2 (en) 2018-11-15
ES3000607T3 (en) 2025-03-03
HRP20241660T1 (hr) 2025-02-14
EP3310809A1 (fr) 2018-04-25
DK3310809T3 (da) 2024-12-02
EP4470557A3 (fr) 2025-02-26
NZ737046A (en) 2019-09-27
MX395147B (es) 2025-03-24
CN118356393A (zh) 2024-07-19
JO3772B1 (ar) 2021-01-31
RS66243B1 (sr) 2024-12-31
TWI725973B (zh) 2021-05-01
US20180134772A1 (en) 2018-05-17
CA2984185A1 (fr) 2016-12-22
MY184266A (en) 2021-03-30
HUE069368T2 (hu) 2025-02-28
IL255443A0 (en) 2017-12-31
HK1245813A1 (en) 2018-08-31
US11498959B2 (en) 2022-11-15
JP2018517727A (ja) 2018-07-05
MX2017016199A (es) 2018-03-01
ZA201707324B (en) 2020-01-29
AR104847A1 (es) 2017-08-16
PT3310809T (pt) 2024-12-16
EA037580B1 (ru) 2021-04-16
MA49726A (fr) 2020-06-10
TW201711697A (zh) 2017-04-01

Similar Documents

Publication Publication Date Title
MA49726B1 (fr) Formulation d'anticorps anti-cgrp
PH12020500240A1 (en) Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
SA519401522B1 (ar) Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات
MA53356B1 (fr) Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations
MA37538B1 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
MA42447A (fr) Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
EP3386536A4 (fr) Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
EP3645742A4 (fr) Anticorps anti-ror1 et leurs procédés de préparation et d'utilisation
MA40513A (fr) Conjugués médicament-anticorps anti-cdh6
MA46770A (fr) Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
MA50949A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA40682B1 (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
MX381232B (es) Formulación de anticuerpos.
EA201792616A1 (ru) Средства, пути применения и способы лечения синуклеопатии
MA40576A (fr) Anticorps et immunoconjugués anti-her2
EA201791093A1 (ru) Антитела к cd47, способы и применение
EA201890278A1 (ru) Антитела к pd-l1
EA201690618A1 (ru) Ингибиторы тирозинкиназы брутона
MA38554A3 (fr) Anticorps bispécifiques dirigés contre fap et dr5, anticorps spécifiques dirigés contre dr5 et leurs procédés d'utilisation
MA39248B1 (fr) Anticorps anti-jagged1 et procédés d'utilisation correspondants
MA35898B1 (fr) Anticorps anti-lrp5 et leurs procédés d'utilisation
MA35712B1 (fr) Anticorps anti-htra1 et leurs procédés d'utilisation
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA201592203A1 (ru) Способы лечения таупатии
EP2968470A4 (fr) Protéines de substance d'inhibition mullerienne (mis) modifiées et leurs utilisations pour le traitement de maladies